ArticleBMC cancer2025
Nanoencapsulation of ferrocene incorporated thiourea and doxorubicin for treatment of acute myeloid leukemia.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myeloid leukemia (AML) is a hematologic malignancy characterized by the accumulation of undifferentiated myeloid precursors in the bone marrow and peripheral blood. Doxorubicin (DOX) is a frontline chemotherapeutic agent that exhibits potent antitumor activity but is hindered by cardiotoxicity, nephrotoxicity, poor solubility, and non-selective distribution. Ferrocene-incorporated thiourea (FITU) has demonstrated anticancer potential but remains limited by hydrophobicity and delivery challenges.
objectiveThe aim of this study was to investigate the therapeutic efficacy of FITU, DOX, and their combination by delivering them through polyethylene glycol (PEG)-coated liposomal nanoparticles.
methodsNanoparticles for doxorubicin (DOX-Nps), Ferrocene incorporated thiourea (FITU), and their combination (FITU + DOX-Nps) were prepared via thin-film hydration and their particle size, surface charge, encapsulation efficiency, and in vitro drug release were characterized. The hemocompatibility, antioxidant activity, and cytotoxicity of the formulations were assessed via standard in vitro assays. In-vivo therapeutic efficacy was evaluated in Wistar rats with benzene-induced AML. Hematological parameters, organ function markers, survival rates, and histopathological analyses of the liver, kidney, and heart were performed. Statistical significance was determined via one-way ANOVA.
resultsThe nanoparticle formulations presented an appropriate size distribution, high encapsulation efficiency, and sustained drug release profiles. Compared to free drugs liposomal formulations demonstrated improved biocompatibility, reduced hemolysis, and enhanced antioxidant and cytotoxic effects, in vitro. In vivo, animals treated with FITU + DOX Nps presented significant restoration of hematological parameters and organ function, improved survival rates and reduced leukemic infiltration in histological assessments. The PEG coated liposomes extended systemic circulation and improved overall therapeutic outcomes.
conclusionCo delivery of FITU and DOX via PEG coated liposomal nanoparticles is a promising strategy for enhancing therapeutic efficacy and minimizing systemic toxicity in AML. These findings support further preclinical development of this nano-formulation as a targeted treatment modality for leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.